Download PDF
Drug Res (Stuttg) 2023; 73(03): 146-155
DOI: 10.1055/a-1924-7746
Original Article

A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients

Alaa Sabri
1   Egyptian Pharmaceutical Vigilance Center, Egyptian Drug Authority
,
Mervat M. Omran
2   Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt
,
S.Abdel Azim
3   Biochemistry Department, Faculty of Pharmacy, Cairo University
,
Raafat Abdelfattah
4   Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt
,
Rasha Mahmoud Allam
5   Cancer Epidemiology and Biostatistics Department, National Cancer Institute, Cairo University, Cairo, Egypt
,
Samia A. Shouman
2   Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Imatinib mesylate (IM) is the gold standard for treatment of Chronic Myeloid Leukemia (CML). This study aimed to gain more knowledge of the altered PK, pharmacogenetic factors, and gene expression leading to variable IM levels. Fifty patients with chronic phase-CML were enrolled in this study and divided as 25 responders and 25 non-responders (patients are directly recruited after response assessment). HPLC/MS/MS was used to determine trough and peak concentration of imatinib and N-desmethyl imatinib in the blood. PCR-RFLP technique was used to detect IDH1 gene mutation (R132). The median value of IM trough level was significantly higher, the P/T ratio was significantly lower and the α-1-acid glycoprotein (AGP) was significantly higher among responders compared to non-responders (P=0.007, 0.009 and 0.048, respectively). Higher N-desmethyl imatinib peak plasma concentration was observed with low mRNA expression of ABCG2 and OCT1 (P=0.01 and 0.037, respectively). IDH1 R132 gene mutation was associated with a significant increase in toxicities (P=0.028). In conclusion, IM trough level, P/T ratio and AGP was significantly higher in responders. In addition, ABCG2 and OCT1 gene expression may affect the interindividual PK variation. Although a prospective study with a larger patient population is necessary to validate these findings. IDH1 mutation is a predictor of increased toxicity with IM treatment.

Key words

CML - Imatinib - N-desmethyl imatinib - mutation - gene expression - OCT1 - IDH1

Supplementary Material



Publication History

Received: 11 April 2022

Accepted: 14 August 2022

Article published online:
11 January 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Faderl S, Talpaz M, Estrov Z. et al. The Biology of Chronic Myeloid Leukemia, N. Engl. J. Med 341 1999; 164-172
    PubMedGoogle Scholar
  • 2 Giotopoulos G, Huntly BJP. CML: new tools to answer old questions. Blood 2020; 135: 2327-2328
    CrossrefPubMedGoogle Scholar
  • 3 Cortes J, Talpaz M, O’Brien S. et al. Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate. Clin. Cancer Res 2005; 11: 3425-3432
    CrossrefPubMedGoogle Scholar
  • 4 Kantarjian H, Sawyers C, Hochhaus A. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med 2002; 346: 645-652
    CrossrefPubMedGoogle Scholar
  • 5 Hochhaus A, Larson RA, Guilhot F. et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N. Engl. J. Med 2017; 376: 917-927
    CrossrefPubMedGoogle Scholar
  • 6 Peng B, Dutreix C, Mehring G. et al. Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion. J. Clin. Pharmacol 2004; 44: 158-162
    CrossrefPubMedGoogle Scholar
  • 7 Quintás-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia. Cancer control 2009; 16: 122-131
    CrossrefPubMedGoogle Scholar
  • 8 Birch M, Morgan PE, Handley S. et al. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib. Biomed. Chromatogr 2013; 27: 335-342
    CrossrefPubMedGoogle Scholar
  • 9 Eechoute K, Sparreboom A, Burger H. et al. Drug Transporters and IM Treatment: Implications for Clinical Practice. Clin. Cancer Res 2011; 17: 406-415
    CrossrefPubMedGoogle Scholar
  • 10 Hu S, Franke RM, Filipski KK. et al. Interaction of IM with human organic ion carriers. Clin. Cancer Res 2008; 14: 3141-3149
    CrossrefPubMedGoogle Scholar
  • 11 Ankathil R, Azlan H, Dzarr AA. et al. Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update. Pharmacogenomics 2018; 19: 475-493
    CrossrefPubMedGoogle Scholar
  • 12 Rinaldetti S, Pfirrmann M, Manz K. et al. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Sub-trial. Clin. Lymphoma Myeloma Leuk 2018; 18: 266-271
    CrossrefPubMedGoogle Scholar
  • 13 Ma Q, Wang J, Wang Y. et al. High IDH1 Expression Is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia. Int. J. Cancer 2015; 137: 1058-1065
    CrossrefPubMedGoogle Scholar
  • 14 Liu X, Gong Y. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomark. Res 2019; 7: 22
    CrossrefPubMedGoogle Scholar
  • 15 Makishima H, Jankowska AM, McDevitt MA. et al. CBL, CBLB, TET2, ASXL1 and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011; 117: e198-e206
    CrossrefPubMedGoogle Scholar
  • 16 Adnan-Awad S, Kankainen M, Mustjoki S. Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. Leuk. Lymphoma 2021; 99: 1087-1099
    PubMedGoogle Scholar
  • 17 Issa GC, Kantarjian HM, Gonzalez GN. et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome – negative metaphases during CML treatment. Blood 2017; 130: 2084-2091
    CrossrefPubMedGoogle Scholar
  • 18 Hughes TP, Kaeda J, Branford S. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med 2003; 349: 1423-1432
    CrossrefPubMedGoogle Scholar
  • 19 Baccarani M, Deininger MW, Rosti G. et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884
    CrossrefPubMedGoogle Scholar
  • 20 Zhang Y, Qiang S, Yu Z. et al. LC-MS-MS Determination of Imatinib and N-Desmethyl Imatinib in Human Plasma. J. Chromatogr. Sci 2014; 52: 344-350
    CrossrefPubMedGoogle Scholar
  • 21 Anthony A, Ankathil R, Ai-Sim G. et al. Influence of ABCB1 C3435T and ABCG2 C421A Gene Polymorphisms in Response to Imatinib Mesylate in Chronic Myeloid Leukemia Patients. Int. J. Environ. Sci. Dev 2012; 3: 274-278
    CrossrefPubMedGoogle Scholar
  • 22 Saußele S, Richter J, Hochhaus A. et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 2016; 30: 1638-1647
    CrossrefPubMedGoogle Scholar
  • 23 Peng B, Hayes M, Resta D. et al. Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial with Chronic Myeloid Leukemia Patients. J. Clin. Oncol 2004; 22: 935-942
    CrossrefPubMedGoogle Scholar
  • 24 Kim K, McMillin GA, Bernard PS. et al. Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia. PLoS One 2019; 14: e0226552
    CrossrefPubMedGoogle Scholar
  • 25 Natarajan H, Kumar L, Bakhshi S. et al. IM trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia, Leuk. Lymphoma 2019; 60: 418-425
    CrossrefPubMedGoogle Scholar
  • 26 Wang Q, Jiang Z-P, Zeng J. et al. Effects of Trough Concentration and Solute Carrier Polymorphisms on IM Efficacy in Chinese Patients with Chronic Myeloid Leukemia. J. Pharm. Pharm. Sci 2020; 23: 1-9
    CrossrefPubMedGoogle Scholar
  • 27 Martins DH, Wagner SC, Dos Santos TV. et al. Monitoring imatinib plasma concentrations in chronic myeloid leukemia. Rev. Bras. Hematol. Hemoter 2011; 33: 302-306
    CrossrefPubMedGoogle Scholar
  • 28 Takahashi N, Miura M, Scott SA. et al. Influence of CYP3A5 and drug transporter polymorphisms on IM trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J. Hum. Genet 2010; 55: 731-737
    CrossrefPubMedGoogle Scholar
  • 29 Zhu Y, Qian S. Clinical efficacy and safety of imatinib in the management of Ph+chronic myeloid or acute lymphoblastic leukemia in Chinese patients. OncoTargets Ther 2014; 7: 395-404
    PubMedGoogle Scholar
  • 30 Omran MM, Abdelfatah R, Mousa H. et al. Relationship between adherence, drug level and clinical response achieved in patients with chronic myeloid leukemia on IM. Ann. Oncol 2016; 27: Vi313-Vi327
    CrossrefPubMedGoogle Scholar
  • 31 Wajid AA, Zeeshan M, Mehmood F. et al. Early molecular response with IM therapy in chronic myeloid leukemia and its association with baseline white blood cell count and spleen size. Pak. Armed Forces med. j. (Online) 2018; 68: 1199-1204
    PubMedGoogle Scholar
  • 32 Etienne G, Guilhot J, Rea D. et al. Long-Term Follow-Up of the French Stop IM (STIM1) Study in Patients with Chronic Myeloid Leukemia. J. Clin. Oncol 2017; 35: 298-305
    CrossrefPubMedGoogle Scholar
  • 33 Ross DM, Branford S, Seymour JF. et al. Safety and efficacy of IM cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-522
    CrossrefPubMedGoogle Scholar
  • 34 Ghallab O, Hamed NAM, El Shafei S. et al. Polymorphism and Outcome in Egyptian Chronic Myeloid Leukaemia Patients. J. Cancer Biol. & Res 2015; 3: 1062-1070
    PubMedGoogle Scholar
  • 35 Tiribelli M, Giusto SD, Toffoletti E. et al. ABCG2 but Not ABCB1 RNA Levels at Diagnosis and during Treatment Correlates with Response to IM and 2G-Tkis Front-Line Therapy in Chronic Phase CML Patients. Blood 2017; 130 Poster
    PubMedGoogle Scholar
  • 36 Bedewy AML, Elmaghraby SM, Kandil NS. ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on IM efficacy. Blood Res 2019; 54: 57-62
    CrossrefPubMedGoogle Scholar
  • 37 Ni LN, Li JY, Miao KR. et al. Multidrug resistance gene (MDR1) polymorphisms correlate with IM response in chronic myeloid leukemia. Med. Oncol 2011; 28: 265-269
    CrossrefPubMedGoogle Scholar
  • 38 Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340-7358
    CrossrefPubMedGoogle Scholar
  • 39 Francis J, Dubashi B, Sundaram R. et al. Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with IM. Med. Oncol 2015; 32: 213
    CrossrefPubMedGoogle Scholar
  • 40 Wang L, Giannoudis A, Lane S. et al. Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to IM in Chronic Myeloid Leukemia. Clin. Pharmacol. Ther 2007; 83: 258-264
    CrossrefPubMedGoogle Scholar
  • 41 Crossman LC, Druker BJ, Deininger MW. hOCT-1 and resistance to IM. Blood 2005; 106: 1133-1134
    CrossrefPubMedGoogle Scholar
  • 42 De Lima LT, Vivona D, Bueno CT. et al. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with IM response in chronic myeloid leukemia. Med. Oncol 2014; 31: 851-859
    CrossrefPubMedGoogle Scholar
  • 43 Giannoudis A, Wang L. et al. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 2013; 121: 628-637
    CrossrefPubMedGoogle Scholar
  • 44 McKenney AS, Levine RL. Isocitrate dehydrogenase mutations in leukemia. J. Clin. Investig 2013; 123: 3672-3677
    CrossrefPubMedGoogle Scholar
  • 45 Roche-Lestienne C, Marceau A, Labis E. et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia 2011; 25: 1661-1664
    CrossrefPubMedGoogle Scholar
  • 46 Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Future Oncol 2018; 14: 979-993
    CrossrefPubMedGoogle Scholar
  • 47 Xu Q, Li Y, Lv N. et al. Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Clin. Cancer Res 2017; 23: 4511-4522
    CrossrefPubMedGoogle Scholar
  • 48 Wagner K, Damm F, Göhring G. et al. Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor. J. Clin. Oncol 2010; 28: 2356-2364
    CrossrefPubMedGoogle Scholar
  • 49 Milojkovic D, Short K, Salisbury JR. et al. Dose-limiting dermatological toxicity secondary to IM mesylate (STI571) in chronic myeloid leukaemia. Leukemia 2003; 17: 1414-1416
    CrossrefPubMedGoogle Scholar
  • 50 Kalmanti L, Saussele S, Lauseker M. et al. Safety and efficacy of IM in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 29: 1123-1132
    CrossrefPubMedGoogle Scholar
  • 51 Natarajan H, Kumar L, Bakhshi S. et al. IM induced toxicity and its influence on cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia. Ann. Oncol 2019; 30 ix92-abstract
    PubMedGoogle Scholar
  • 52 Malhotra H, Sharma P, Bhargava S. et al. Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia. Leuk Lymphoma 2014; 55: 2614-2623
    CrossrefPubMedGoogle Scholar
  • 53 Dhand NK, Khatkar MS. Statulator: An online statistical calculator. Sample Size Calculator for Comparing Two Independent Means. 2014
    PubMedGoogle Scholar